PerkinElmer, Inc. (PKI)
(Delayed Data from NYSE)
$96.59 USD
+1.71 (1.80%)
Updated May 3, 2019 04:03 PM ET
After-Market: $96.59 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$96.59 USD
+1.71 (1.80%)
Updated May 3, 2019 04:03 PM ET
After-Market: $96.59 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
LabCorp & Interpace Team Up, Drive Specialty Diagnostics
by Zacks Equity Research
Per the new deal with Interpace, Dianon Pathology, member of the LabCorp (LH) Specialty Testing Group, is supposed to perform the thyroid biopsy analysis.
DaVita (DVA) Banks on Kidney Care Unit Amid Labor Union Woes
by Zacks Equity Research
Davita's kidney care unit is gaining prominence worldwide. However, the company is grappling with labor-union woes in California and Ohio.
Varian Medical's ProBeam Platform Gains Traction in Russia
by Zacks Equity Research
Varian Medical's (VAR) ProBeam system is a leading platform in advanced cancer-care technologies.
CVS Health's Pharmacy Services Remain Solid Amid Retail Drag
by Zacks Equity Research
CVS Health's (CVS) robust 2018 PBM selling season is an upside. We are also upbeat about the company's initiation of the crucial $69-billion acquisition of Aetna.
Thermo Fisher Scientific Buys IntegenX, Widens HID Suite
by Zacks Equity Research
Thermo Fisher Scientific (TMO) forges ahead with initiatives to strengthen its hold in the high-potential human identification market.
What's Driving Orthofix International to a New 52-Week High
by Zacks Equity Research
Orthofix International is (OFIX) strong on recent buyouts as well as the FDA approval.
BioScrip's Dull 2017 Earnings a Woe, Core Business Robust
by Zacks Equity Research
BioScrip's (BIOS) strategy to specifically focus on core revenue mix hurts overall growth. However, the company's core infusion business remains strong.
Orthofix to Buy Spinal Kinetics, Widens Spine Fixation Suite
by Zacks Equity Research
Orthofix's (OFIX) latest deal to boost Spine Fixation portfolio and strengthen hold in the high-potential artificial disc market buoys optimism.
Here's Why You Should Invest in Varian Medical Right Now
by Zacks Equity Research
Varian Medical (VAR) banks on regulatory tidings and acquisition.
Here's Why You Should Invest in AmerisourceBergen Right Now
by Zacks Equity Research
AmerisourceBergen's (ABC) consistent pursuit of acquisitions to strengthen core areas buoys optimism.
QIAGEN's QFT-Plus Endorsed for Latent Tuberculosis Screening
by Zacks Equity Research
QIAGEN's (QGEN) QuantiFERON-TB diagnostic test kit falls under QIAGEN's Molecular Diagnostics segment, which was the highest revenue grosser in the last reported quarter.
Varian Medical Receives Regulatory Nod for Sirtex Buyout
by Zacks Equity Research
The acquisition of Sirtex will fortify Varian Medical's (VAR) footprint in Australia. The transaction is likely to close in late May 2018.
Medtronic's (MDT) Guardian Connect CGM System Wins FDA Nod
by Zacks Equity Research
Medtronic (MDT) continues to add initiatives to bolster the Diabetes segment.
Cooper Companies Banks on Specialty Lenses, Competition Rife
by Zacks Equity Research
Cooper Companies' (COO) flagship silicone hydrogel lenses are expected to see strong sales in the quarters ahead.
Medtronic's Positive Study Results May Boost CSH Business
by Zacks Equity Research
Medtronic, (MDT) presenting favorable results from the studies based on the CoreValve TAVR system might boost the top line, with increased uptake of the product.
Laborie Medical Technologies to Acquire Cogentix Medical
by Zacks Equity Research
Laborie Medical Technologies will buy all of the outstanding shares of Cogentix Medical (CGNT) for a net worth of $239 million.
Illumina Banks on Product Launches & Strategic Partnerships
by Zacks Equity Research
Illumina (ILMN) successfully broadens base by enriching its portfolio of sequencing products and building strategic partnerships with therapeutic and diagnostic service providers.
Accuray Gains on Radixact Unit, Solid Geographical Foothold
by Zacks Equity Research
Radixact and TomoTherapy along with solid global prospects are the key catalysts for Accuray (ARAY).
ABIOMED (ABMD) Banks on Impella Platform, Competition Rife
by Zacks Equity Research
Impella, ABIOMED's (ABMD) flagship product line, continues to be growth driver.
Varian (VAR) to Equip 7 Centers in Mexico, Expand in Oncology
by Zacks Equity Research
Varian's (VAR) Edge radiosurgery system will allow physicians to treat tumors noninvasively in Mexico.
IDEXX Laboratories Gains on Solid Prospects & CAG Business
by Zacks Equity Research
IDEXX Laboratories (IDXX) continues to boost investor confidence in strong companion animal business along with attractive global prospects.
BioScrip (BIOS) Loss Widens in Q4, '18 View Holds Promise
by Zacks Equity Research
BioScrip's (BIOS) strategic shift toward raising its core revenue mix hampers growth. However, guidance for 2018 buoys optimism on the stock.
GNC Holdings Expands in India, Boosts International Business
by Zacks Equity Research
GNC Holdings (GNC) adopts initiatives to increase contributions from international business.
Cooper Companies (COO) Tops Q1 Earnings & Revenue Estimates
by Zacks Equity Research
Cooper Companies (COO) Q1 results gain from strength in CooperVision segment.
4 Factors Driving Edwards Lifesciences to a New 52-Week High
by Zacks Equity Research
Edwards Lifesciences (EW) strong on recent buyouts and CE Mark.